In this section

Filter by year:
Back

News & events


  • Galapagos extends drug discovery collaboration with Amgen into 2010


    Thu 18 Dec 2008
    Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen’s discovery programs.

  • Scott Snyder to head BioFocus DPI Compound Management


    Mon 15 Dec 2008
    BioFocus DPI announced today that Scott Snyder has joined as Senior Director of Compound Management at BioFocus DPI’s compound management facility in South San Francisco, CA, USA.

  • BioFocus DPI and Dart Neuroscience LLC sign drug discovery and compound management agreements


    Tue 09 Dec 2008
    BioFocus DPI and Dart Neuroscience LLC (DNS) announced today new collaboration agreements in drug discovery and compound management. Total potential value of the contracts for BioFocus DPI is €4.1 million (US$5.4 million) over three years.

  • Galapagos and Merck Serono enter new collaboration agreements


    Tue 18 Nov 2008
    Mechelen, Belgium; Galapagos NV (Euronext: GLPG) announced today new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is €1.1 million over one year.

  • BioFocus DPI and ZoBio announce marketing agreement


    Thu 13 Nov 2008
    BioFocus DPI and ZoBio announced today that they have signed a worldwide marketing and sales agreement for ZoBio’s fragment-based NMR technologies. Under the terms of the agreement BioFocus DPI will sell ZoBio’s services either as a standalone offering or in combination with BioFocus DPI’s drug discovery offering.

  • Galapagos sells San Diego chemistry facility to ChemVentures


    Wed 05 Nov 2008
    Mechelen, Belgium; 5 November 2008 – Galapagos NV (Euronext: GLPG) announces today that it has completed the sale of its BioFocus DPI chemistry facility in San Diego to ChemVentures Pty Ltd, an Australian discovery research group. Financial terms were not disclosed.

  • Galapagos and CHDI enter new collaboration agreements


    Wed 29 Oct 2008
    Mechelen, Belgium and Los Angeles, USA; 29 October 2008 – Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit organization pursuing treatments for Huntington’s disease (HD), announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD.

  • Enhanced decision support software streamlines data access and integration


    BioFocus DPI releases new version of StarDrop
    Wed 08 Oct 2008
    BioFocus DPI has released an enhanced version of its StarDrop software for guiding decisions in drug discovery. StarDrop 4.2 allows users to directly access data from multiple sources and to interface with other industry standard informatics platforms such as Pipeline Pilot®. By placing StarDrop at the centre of the drug discovery process and applying its unique approach for identifying high quality chemistry, users can maximize the likelihood of success.

  • BioFocus DPI launches seven new libraries including its first libraries targeting proteases


    Wed 24 Sep 2008
    BioFocus DPI announces the launch of seven new biologically-targeted libraries of novel drug-like compounds. These libraries specifically target ion channels, kinases and for the first time, proteases – three of the most important protein classes for drug discovery.

  • Cutting-edge meeting on ion channel drug discovery


    Innovative technology unlocks a challenging target class
    Wed 17 Sep 2008
    The latest technology in ion channel drug discovery will be discussed at a two-day meeting to be held at the Nucleus Conference Facility – Chesterford Research Park, Saffron Walden, UK, on October 9th and 10th 2008. Jointly organized by BioFocus DPI and Molecular Devices, now part of MDS Analytical Technologies, the meeting will focus on screening technologies such as automated patch-clamp, and how these have revolutionized ion channel research.

  • OneWorld Health and BioFocus DPI expand collaboration to develop new drugs for the treatment of childhood diarrheal diseases


    BioFocus DPI to perform high-throughput screening
    Thu 11 Sep 2008
    BioFocus DPI, the service division of Galapagos, and the Institute for OneWorld Health, a non-profit pharmaceutical company, announced today that it had expanded its 2006 collaboration in diarrheal disease drug discovery.

  • BioFocus DPI adds structural biology to its drug discovery services


    Tue 26 Aug 2008
    Galapagos NV and Sareum Holdings plc announce today that Galapagos has acquired Sareum’s assets in drug discovery services, for a total cash consideration of €695,000 (£553,000). These assets will expand and strengthen Galapagos’ service division, BioFocus DPI, by adding structural biology to its pre-clinical drug discovery capabilities.

  • UCB transfers UK-based medicinal chemistry program to BioFocus DPI


    Tue 12 Aug 2008
    Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB’s medicinal chemistry programs. The total contract value for Galapagos could potentially exceed €4M.

  • BioFocus DPI transfers predictive drug discovery databases to EMBL’s European Bioinformatics Institute


    Wed 23 Jul 2008
    Wellcome Trust grant makes data publicly available to researchers BioFocus DPI announces the transfer of its databases for predictive drug discovery to the EMBL’s European Bioinformatics Institute (EMBL-EBI). The data will become publicly available on-line to drug discovery researchers worldwide through the EMBLEBI under license from Galapagos, BioFocus DPI’s parent company.

  • NIH extends agreement with BioFocus DPI


    Tue 22 Jul 2008
    The U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos’ service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010. According to the terms of this agreement, BioFocus DPI will receive more than $9 million (€5.7 million) over the course of the two year extension.

  • Boehringer Ingelheim licenses drug targets from autoimmune collaboration with BioFocus DPI


    Thu 17 Jul 2008
    BioFocus DPI announced today that Boehringer Ingelheim has exercised its right to license two drug targets from its autoimmune research agreement, resulting in a milestone payment to BioFocus DPI.

  • BioFocus DPI signs new compound management agreement


    Mon 30 Jun 2008
    BioFocus DPI will provide compound management and related services to Sepracor Inc., a leader in respiratory and central nervous system disorder medicines. Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a period of three years.

  • California stem Cell and BioFocus DPI to collaborate in ALS Association-funded research using human motor neurons


    MOTORPLATE™ 96 Assay-Ready Well Plates Enable High Throughput and High Content Screening Assays
    Tue 20 May 2008
    California Stem Cell, Inc. (CSC) will supply international drug discovery organization BioFocus DPI, the service division of Galapagos, with its MOTORPLATE™ 96 assay-ready well plates, containing motor neuron progenitors (MNPs) derived from human embryonic stem cells (hESC).

  • BioFocus DPI to perform medicinal chemistry services for UCL research project


    Mon 19 May 2008
    Galapagos NV (Euronext: GLPG) announced today that is has signed a drug discovery research agreement with UCL (University College London). Galapagos’ BioFocus DPI service division will perform medicinal chemistry services for a UCL research project. It is also intended that BioFocus DPI will offer UCL ADME screening facilities during the appropriate stages of the work.

  • Galapagos and Allergan enter drug discovery collaboration


    Tue 06 May 2008
    Mechelen, Belgium; 6 May 2008 – Galapagos NV (Euronext: GLPG) announced today that Galapagos’ service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to €1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.

  • BioFocus DPI releases five new compound libraries


    Tue 08 Apr 2008
    BioFocus DPI today introduces new FieldFocus and SoftFocus libraries that were created with advanced modeling tools. The libraries consist of novel drug-like compounds specifically targeted towards kinases and voltage-dependent ion channels. These targets represent two of the most important and commonly studied protein classes for drug discovery.

  • BioFocus DPI launches ‘Intelligent Screening’ platform at SBS


    New approach to accelerating drug discovery programs
    Mon 07 Apr 2008
    BioFocus DPI is launching a new approach to discovery biology at the Society for Biomolecular Sciences Annual Conference taking place in St. Louis. Called ‘Intelligent Screening’, this approach focuses on combining the know-how and expertise of BioFocus DPI’s scientists with extensive high-throughput and information-rich screening capabilities to generate faster results and accelerate partners’ drug discovery programs.

  • BioFocus DPI takes global license for Cresset’s molecular field software


    Wed 19 Mar 2008
    BioFocus DPI and Cresset BioMolecular Discovery announced today that BioFocus DPI has up-graded its software license with Cresset to provide global access to the entire range of Cresset’s molecular field software for use in drug discovery.

  • BioFocus DPI to distribute NIH’s Clinical Compound Collection


    Tue 18 Mar 2008
    BioFocus DPI, a Galapagos Company, announces the launch of the U.S. National Institutes of Health Clinical Compound Collection (NCC). The collection currently contains 446 bioactive compounds, most of which are known drugs. The NCC is managed and distributed through BioFocus DPI’s Compound Management facility, home to the NIH’s Molecular Libraries Small Molecule Repository.

  • BioFocus DPI launches ADME/PK service and software platform


    Tue 19 Feb 2008
    BioFocus DPI announces the launch of ADME/PK Laboratory and the StarDropTM software platform.

  • Galapagos extends drug discovery collaboration with Lilly in nuclear hormone receptor research


    Mon 14 Jan 2008
    Galapagos NV announced today that its service division BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2008. BioFocus DPI will screen certain compounds as provided by Lilly against certain selected assays in quarterly screening regimes to identify active compounds and provide selectivity information to Lilly for Lilly’s nuclear hormone receptor research program.

  • Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutical


    Thu 03 Jan 2008
    Galapagos NV (Euronext & LSE: GLPG) announced today a new two-year target discovery collaboration between Janssen Pharmaceutica and BioFocus DPI, Galapagos’ service division, in the field of oncology. BioFocus DPI will apply Galapagos’ proprietary adenoviral platform to identify novel drug targets for the development of cancer therapies.



Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend


Related links


Get in contact with us









Where to find usSubscribe to the RSS feed



    view all events

     


    BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.